Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Body's anti-HIV drug explained

Body's anti-HIV drug explained

October 13, 2008

Nature study reveals long-sought atomic structure of key enzyme and suggests new approach for drug development

Humans have a built-in weapon against HIV, but until recently no one knew how to unlock its potential.




A study published online by the journal Nature reveals the atomic structure of this weapon - an enzyme known as APOBEC-3G - and suggests new directions for drug development.

APOBEC-3G is present in every human cell. It is capable of stopping HIV at the first step of replication, when the retrovirus transcribes its RNA into viral DNA.

The study's authors, led by Xiaojiang Chen of the University of Southern California, were able to show the atomic structure of the active portion of APOBEC-3G.

The discovery suggests how and where the enzyme binds to the viral DNA, mutating and destroying it.

"We understand how this enzyme can interact with DNA," said Chen, a professor of molecular and computational biology at USC. "This understanding provides a platform for designing anti-HIV drugs."

If APOBEC-3G works so well, why do people get AIDS? Because the HIV virus has evolved to encode the protein Vif, known as a "virulence factor," that blocks APOBEC-3G.

With APOBEC-3G out of the way, the RNA of the HIV virus can be successfully transcribed to viral DNA, an essential step for infection and for producing many more HIV viruses.

Chen said his group's research offers important clues on where Vif binds to APOBEC-3G. The knowledge could be used to design drugs that would prevent Vif from binding and allow APOBEC-3G to do its job, Chen said.

That would unlock humans' innate ability to fight HIV.

"We were born with it, and it's there waiting," Chen said.

In addition to fighting HIV, APOBEC-3G can inhibit the Hepatitis B virus. Other members of the APOBEC family serve important roles in antibody maturation, fat metabolism and heart development.

Mapping the structure of APOBEC-3G at the atomic level is a goal that "has been sought after worldwide because of its significance," Chen said.

University of Southern California



Related Anti-HIV Drug Current Events and Anti-HIV Drug News Articles
HIV drug resistance risk in mothers reduced by combination of common drugs
New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
UCLA scientists, along with collaborators from Purdue University, have demonstrated that HIV protease inhibitors - crucial drugs for HIV treatment - block a cellular enzyme important for generating the structural scaffolding for the cell nucleus.

Hepatitis B drug can compromise HIV treatment
Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal.

Combination microbicides protect monkeys against HIV-like virus
Experiments in female monkeys have for the first time shown that when used in combination, vaginal gels known as microbicides can protect against an HIV-like virus.

Harmless virus may hold key to more effective HIV drug discovery
A simple, harmless virus might hold the key to the more effective and efficient development of HIV and anti-viral drugs, UCI chemical biologists have found.
More Anti-HIV Drug Current Events and Anti-HIV Drug News Articles
Two new anti-HIV drugs provide effective combo.(Infectious Diseases): An article from: Family Practice News
by Mitchel L. Zoler

This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2005. The length of the article is 575 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Blood fat levels and anti-HIV drugs: now what?: An article from: HIV Treatment: ALERTS!
by Ben J. Barnett, Mario Maldonado

This digital document is an article from HIV Treatment: ALERTS!, published by The Center for AIDS: Hope & Remembrance Project on July 1, 2001. The length of the article is 1960 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop aims ... (The national gay & lesbian newsmagazine)
by Fred Kuhr

This digital document is an article from The Advocate (The national gay & lesbian newsmagazine), published by Thomson Gale on April 10, 2007. The length of the article is 902 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

T-20, New Kind of Anti-HIV Drug, Looks Good.: An article from: Family Practice News
by Mitchel L. Zoler

This digital document is an article from Family Practice News, published by International Medical News Group on February 15, 2000. The length of the article is 2725 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

FDA APPROVES GILEAD'S ANTI-HIV DRUG VIREAD.: An article from: Biotech Business

This digital document is an article from Biotech Business, published by Worldwide Videotex on December 1, 2001. The length of the article is 1206 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Antidepressants may enhance anti-HIV activity.(drug use): An article from: Clinical Psychiatry News
by Damian McNamara

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on May 1, 2006. The length of the article is 613 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Anti-HIV Agents, Drugs and Substances: Index and Medical Analysis of New Research Information
by Abbe Research Division

Anti-HIV Drugs (Information)

Tenofovir good add-on drug for resistant HIV infections. (New Anti-HIV Therapy).(Brief Article): An article from: Internal Medicine News

This digital document is an article from Internal Medicine News, published by International Medical News Group on March 1, 2002. The length of the article is 498 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Anti-HIV fusion inhibitors poised for release next year. (New Class of Drugs).: An article from: Internal Medicine News

This digital document is an article from Internal Medicine News, published by International Medical News Group on August 15, 2002. The length of the article is 592 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

© 2009 BrightSurf.com